{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:39:00Z","timestamp":1771951140795,"version":"3.50.1"},"reference-count":239,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T00:00:00Z","timestamp":1412208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Reumatologia"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.rbr.2014.06.006","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T19:15:44Z","timestamp":1413227744000},"page":"281-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Seguran\u00e7a do uso de terapias biol\u00f3gicas para o tratamento de artrite reumatoide e espondiloartrites"],"prefix":"10.1186","volume":"55","author":[{"given":"Licia Maria Henrique da","family":"Mota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00f3ris Afonso","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claiton Viegas","family":"Brenol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Feldman","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldo da Rocha Castelar","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ieda Maria Magalh\u00e3es","family":"Laurindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e2nio Alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joz\u00e9lio Freire de","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoel Barros","family":"Bertolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo de Medeiros","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max Victor Carioca","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilzio Ant\u00f4nio da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Louzada\u2010J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percival Degrava","family":"Sampaio\u2010Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina Dalva Neubarth","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Aires Corr\u00eaa","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Eduardo Coelho","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Supl 6","key":"10.1016\/j.rbr.2014.06.006_bib0005","first-page":"vi28","article-title":"Evolution of treatment for rheumatoid arthritis","volume":"5","author":"Upchurch","year":"2012","journal-title":"Rheumatology (Oxford)."},{"issue":"Supl 1","key":"10.1016\/j.rbr.2014.06.006_bib0010","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1478-6354-13-S1-S5","article-title":"Advances in rheumatology: new targeted therapeutics","volume":"13","author":"Tak","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.rbr.2014.06.006_bib0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11882-012-0307-y","article-title":"Cellular targeting in autoimmunity","volume":"12","author":"Rogers","year":"2012","journal-title":"Curr Allergy Asthma Rep."},{"key":"10.1016\/j.rbr.2014.06.006_bib0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.berh.2012.03.003","article-title":"Taking advances from bench to bedside during the last decade","volume":"26","author":"Kok","year":"2012","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2302\/kjm.60.75","article-title":"Revolutionary change in rheumatoid arthritis management with biological therapy","volume":"60","author":"Takeuchi","year":"2011","journal-title":"Keio J Med."},{"key":"10.1016\/j.rbr.2014.06.006_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/S0482-50042012000100002","article-title":"Switching between anti\u2010TNF\u2010alpha agents does not improve functional capacity in patients with long\u2010term standing and active rheumatoid arthritis","volume":"52","author":"Soares","year":"2012","journal-title":"Rev Bras Reumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.rbr.2014.06.006_bib0040","first-page":"72","article-title":"Tumor necrosis factors blocking agents: analogies and differences","volume":"83","author":"Benucci","year":"2012","journal-title":"Acta Biomed."},{"key":"10.1016\/j.rbr.2014.06.006_bib0045","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease\u2010modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease\u2010modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0060","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1590\/S0482-50042013000300003","article-title":"Recomenda\u00e7\u00f5es sobre o Diagn\u00f3stico e Tratamento da Espondilite Anquilosante 2012","volume":"53","author":"Sampaio-Barros","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.rbr.2014.06.006_bib0065","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 Update of the international ASAS recommendations for the use of anti\u2010TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0070","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1590\/S0482-50042013000300002","article-title":"Recomenda\u00e7\u00f5es sobre o Diagn\u00f3stico e Tratamento da Artrite Psori\u00e1sica 2012","volume":"53","author":"Carneiro","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.rbr.2014.06.006_bib0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/rheumatology\/keq325","article-title":"Long\u2010term effectiveness and safety of TNF\u2010blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register","volume":"50","author":"Kievit","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long\u2010term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbr.2014.06.006_bib0085","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/rheumatology\/keq326","article-title":"Ten years with biologics: to whom do data on effectiveness and safety apply?","volume":"50","author":"Simard","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0090","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","article-title":"Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long\u2010term outcome","volume":"50","author":"Baraliakos","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0095","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.2007.078139","article-title":"Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis","volume":"67","author":"Davis","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0100","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2011-200358","article-title":"Early response to adalimumab predicts long\u2010term remission through 5 years of treatment in patients with ankylosing spondylitis","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/ard.2011.154799","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104\u2010week results of the GO\u2010RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0110","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti\u2010TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.rbr.2014.06.006_bib0115","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.rbr.2014.06.006_bib0120","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0125","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/ard.2008.100149","article-title":"Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging","volume":"69","author":"Anandarajah","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0135","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0140","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0145","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrrheum.2011.145","article-title":"Safety of biologic therapy in rheumatoid arthritis","volume":"7","author":"Woodrick","year":"2011","journal-title":"Nat Rev Rheumatol."},{"issue":"Supl. 5","key":"10.1016\/j.rbr.2014.06.006_bib0150","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/rheumatology\/kes114","article-title":"Assessing the safety of biologic agents in patients with rheumatoid arthritis","volume":"51","author":"Rubbert-Roth","year":"2012","journal-title":"Rheumatology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0155","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time\u2010dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0160","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/ard.2009.125658","article-title":"Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists","volume":"69","author":"Garc\u00eda-Doval","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti\u2010TNF\u2010alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA."},{"key":"10.1016\/j.rbr.2014.06.006_bib0170","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0175","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug\u2010specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti\u2010TNF therapy: results from the British Society of Rheumatology Biologic Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0180","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta\u2010analysis and Cochrane overview","volume":"16","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"10.1016\/j.rbr.2014.06.006_bib0185","first-page":"152","article-title":"Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis","volume":"52","author":"da Mota","year":"2012","journal-title":"Rev Bras Reumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0190","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","article-title":"Influence of replacing tuberculin skin test with ex vivo interferon \u03b3 release assays on decision to administer prophylactic antituberculosis antibiotics before anti\u2010TNF therapy","volume":"71","author":"Mariette","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.reuma.2012.04.007","article-title":"Lesiones cut\u00e1neas y terapia biol\u00f3gica con antagonistas del factor de necrosis tumoral","volume":"9","author":"Hern\u00e1ndez","year":"2013","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.rbr.2014.06.006_bib0200","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti\u2010tumor necrosis factor alpha monoclonal antibody combined with low\u2010dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0205","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rbr.2014.06.006_bib0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti\u2010tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0215","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty\u2010two\u2010week, phase III, multicenter, randomized, double\u2010blind, placebo\u2010 controlled, parallel\u2010group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0220","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO\u2010FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/rheumatology\/ker321","article-title":"Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisals","volume":"51","author":"Kiely","year":"2012","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0230","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2036.2012.05189.x","article-title":"Non\u2010malignant haematological complications of anti\u2010tumour necrosis factor alpha therapy","volume":"36","author":"Bessissow","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rbr.2014.06.006_bib0235","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","article-title":"Anti\u2010tumor necrosis factor alpha terapy in rheumatoid arthritis: an update on safety","volume":"63","author":"Hyrich","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0240","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-139-3-200308050-00021-w4","article-title":"Severe neutropenia and thrombocytopenia associated with infliximab","volume":"139","author":"Vidal","year":"2003","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rbr.2014.06.006_bib0245","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/rheumatology\/kem332","article-title":"Three significant cases of neutropenia with etanercept","volume":"47","author":"Wenham","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0250","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF\u2010targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0255","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double\u2010edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.rbr.2014.06.006_bib0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrneurol.2011.1","article-title":"Monoclonal antibody therapy\u2010associated neurological disorders","volume":"7","author":"Bosch","year":"2011","journal-title":"Nat Rev Neurol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0265","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0270","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneurol.2009.11","article-title":"Long term course of demyelinating neuropathies occurring during tumor necrosis factor alpha blocker therapy","volume":"66","author":"Lozeron","year":"2009","journal-title":"Arch Neurol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0275","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of placebo\u2010controlled multicenter study","volume":"53","year":"1999","journal-title":"Neurology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0280","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti\u2010tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0285","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.semarthrit.2010.06.004","article-title":"Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review","volume":"40","author":"Fern\u00e1ndez-Espartero","year":"2011","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0290","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/ard.2009.111500","article-title":"Demyelinating events in rheumatoid arthritis after drug exposures","volume":"69","author":"Bernatsky","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0295","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/art.21560","article-title":"Contribution of Congestive Heart Failure and Ischemic Heart Disease to Excess Mortality in Rheumatoid Arthritis","volume":"54","author":"Nicola","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0300","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/BOR.0b013e328133f58e","article-title":"Cardiovascular Risks in Spondyloarthritides","volume":"19","author":"Heeneman","year":"2007","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0305","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.biopha.2006.09.006","article-title":"Cardiovascular disease in Rheumatoid Arthritis","volume":"60","author":"Gonzalez-Gay","year":"2006","journal-title":"Biomed Pharmacother."},{"key":"10.1016\/j.rbr.2014.06.006_bib0310","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N Eng J Med."},{"key":"10.1016\/j.rbr.2014.06.006_bib0315","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure. Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation."},{"key":"10.1016\/j.rbr.2014.06.006_bib0320","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.rbr.2014.06.006_bib0325","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rbr.2014.06.006_bib0330","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/01.RES.0000043825.01705.1B","article-title":"Inflammatory mediators and the failing heart: past, present, and the foreseeable future","volume":"91","author":"Mann","year":"2002","journal-title":"Circ Res."},{"key":"10.1016\/j.rbr.2014.06.006_bib0335","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/rheumatology\/kem033","article-title":"A placebo\u2010controlled, randomized, double\u2010blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases","volume":"46","author":"Weisman","year":"2007","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0340","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0345","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2006.067660","article-title":"All\u2010cause and cause\u2010specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists","volume":"66","author":"Carmona","year":"2007","journal-title":"Ann Rheum Dis."},{"issue":"Suppl. II","key":"10.1016\/j.rbr.2014.06.006_bib0350","first-page":"307","article-title":"Analysis of risk factors and effect of treatment on the development of cardiovascular disease in patients with rheumatoid arthritis","volume":"65","author":"Kremer","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0355","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1185\/030079908X261177","article-title":"The incidence and prevalence of extra\u2010articular and systemic manifestations in a cohort of newly\u2010diagnosed patients with rheumatoid arthritis between 1999 and 2006","volume":"24","author":"Hochberg","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.rbr.2014.06.006_bib0360","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1002\/art.22255","article-title":"Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis","volume":"54","author":"Solomon","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0365","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2383","article-title":"Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST\u2010RA study","volume":"10","author":"Naranjo","year":"2008","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.rbr.2014.06.006_bib0370","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti\u2010tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0375","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/art.22094","article-title":"Antirheumatic drug use and the risk of acute myocardial infarction","volume":"55","author":"Suissa","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0380","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/ard.2008.089862","article-title":"Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis","volume":"68","author":"Radovits","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"Suppl","key":"10.1016\/j.rbr.2014.06.006_bib0385","first-page":"S535","article-title":"Combination TNF\u2010inhibitor\u2010methotrexate therapyis superior to methotrexate monotherapy in reducing the risk of acute myocardial infarction in patients with rheumatoid arthritis","volume":"56","author":"Singh","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0390","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.23811","article-title":"The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case\u2010control analysis","volume":"58","author":"Wolfe","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.rbr.2014.06.006_bib0395","first-page":"S311","article-title":"Rates of myocardial infarction (MI) and cerebrovascular accident (CVA) in patients with rheumatoid arthritis (RA) treated with anti\u2010TNF therapy: results from the British Society of Rheumatology Biologics Register (BSRBR)","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0400","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0405","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/rheumatology\/kem212","article-title":"Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF\u2010alpha antagonists","volume":"46","author":"Curtis","year":"2007","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0410","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00296-006-0215-3","article-title":"The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists","volume":"27","author":"Cole","year":"2007","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.rbr.2014.06.006_bib0415","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti\u2010tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med."},{"key":"10.1016\/j.rbr.2014.06.006_bib0420","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ahj.2008.02.025","article-title":"Tumor necrosis factor\u2010alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis","volume":"156","author":"Setoguchi","year":"2008","journal-title":"Am Heart J."},{"key":"10.1016\/j.rbr.2014.06.006_bib0425","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/rheumatology\/keh610","article-title":"Anti\u2010rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis","volume":"44","author":"Bernatsky","year":"2005","journal-title":"Rheumatology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0430","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.rdc.2012.09.006","article-title":"Malignancy risks with biologic therapies","volume":"38","author":"Cush","year":"2012","journal-title":"Rheum Dis Clin N Am."},{"key":"10.1016\/j.rbr.2014.06.006_bib0435","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/art.30653","article-title":"Observational studies on the risk of cancer associated with tumor factor inhibitors in rheumatoid arthritis: a review of their methodologies and results (review)","volume":"64","author":"Solomon","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0440","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatic arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0445","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta\u2010analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0450","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non\u2010melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0455","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta\u2010analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.rbr.2014.06.006_bib0460","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"41","author":"Carmona","year":"2011","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0465","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0470","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000300136","article-title":"Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF\u2010alpha antagonists and melanocytic proliferation","volume":"221","author":"Katoulis","year":"2010","journal-title":"Dermatology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0475","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00105-008-1695-8","article-title":"Long term treatment of psoriasis with TNF\u2010alpha antagonists Occurrence of malignant melanoma","volume":"60","author":"Kowalzick","year":"2009","journal-title":"Hautarzt."},{"key":"10.1016\/j.rbr.2014.06.006_bib0480","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2230.2008.02970.x","article-title":"Primary cutaneous melanoma: a complication of infliximab treatment","volume":"34","author":"Khan","year":"2009","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0485","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1365-4632.2010.04570.x","article-title":"The role of drugs in the induction and\/or exacerbation of psoriasis","volume":"49","author":"Basavaraj","year":"2010","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0490","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/RHU.0b013e31816b95ea","article-title":"Anti\u2010TNF agents inducing psoriasis: a recognized adverse effect","volume":"14","author":"Scheinberg","year":"2008","journal-title":"J Clin Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0495","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side\u2010effects in patients with rheumatic diseases during application of tumour necrosis factor\u2010alpha antagonists","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0500","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new\u2010onset psoriasis in patients with rheumatoid arthritis receiving anti\u2010tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0505","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF\u2010blockade therapy: a review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.rbr.2014.06.006_bib0510","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF\u2010{alpha} inhibitors in patients with rheumatologic conditions","volume":"143","author":"De Gannes","year":"2007","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0515","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1365-2133.2005.06977.x","article-title":"Infliximab can precipitate as well as worsen palmo plantar pustulosis: possible linkage to the expression of tumour necrosis factor\u2010alpha in the normal palmar eccrine sweat duct","volume":"153","author":"Michaelsson","year":"2005","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0520","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0525","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isomaki","year":"1978","journal-title":"J Chronic Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0530","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/art.27402","article-title":"Do rheumatoid arthritis and lymphoma share risk factors?. a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis","volume":"62","author":"Hellgren","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0535","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","article-title":"Risk of cancer in patients receiving non\u2010biologic disease\u2010modifying therapy for rheumatoid arthritis compared with the UK generalpopulation","volume":"52","author":"Mercer","year":"2013","journal-title":"Rheumatology (Oxford)."},{"issue":"317","key":"10.1016\/j.rbr.2014.06.006_bib0540","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case\u2010control study","volume":"18","author":"Baecklund","year":"1998","journal-title":"BMJ."},{"key":"10.1016\/j.rbr.2014.06.006_bib0545","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0550","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta\u2010analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.rbr.2014.06.006_bib0555","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty\u2010six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0560","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti\u2010tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0565","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.autrev.2009.07.006","article-title":"Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry","volume":"9","author":"Pallavicini","year":"2010","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.rbr.2014.06.006_bib0570","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti\u2010TNF: results of the 3\u2010year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0575","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti\u2010tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0580","series-title":"TNF inhibitors (TNF\u2010I) and risk of malignancy in 8,072 RA patients followed over 15,495 patient years (Abstract 282)","author":"Greenberg","year":"2007"},{"key":"10.1016\/j.rbr.2014.06.006_bib0585","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti\u2010tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0590","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rbr.2014.06.006_bib0595","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","article-title":"Immunogenicity of Anti\u2010TNF\u2010alpha agents in autoimmune diseases","volume":"38","author":"Aikawa","year":"2010","journal-title":"Clin Rev Allergy Immunol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0600","doi-asserted-by":"crossref","first-page":"R666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF\u2010alpha\u2010blocking therapy in patients with rheumatoid arthritis: a prospective study","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.rbr.2014.06.006_bib0605","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0025-6196(11)60668-X","article-title":"Lupus\u2010like syndrome attributable to anti\u2010tumor necrosis factor alpha therapy in 14 patients during an 8\u2010year period at Mayo Clinic","volume":"84","author":"Wetter","year":"2009","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.rbr.2014.06.006_bib0610","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2230.2004.01471.x","article-title":"Discoid lupus erythematosus\u2010like eruption induced by infliximab","volume":"29","author":"Stratigos","year":"2004","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0615","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug\u2010induced lupus due to anti\u2010tumor necrosis factor alpha agents","volume":"37","author":"Costa","year":"2008","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0620","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1346-8138.2010.00951.x","article-title":"Cutaneous lupus erythematosus induced by adalimumab","volume":"38","author":"Vezzoli","year":"2011","journal-title":"J Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0625","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archderm.140.8.1012-a","article-title":"Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles","volume":"140","author":"Ettefagh","year":"2004","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0630","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/archderm.141.6.759","article-title":"Recurrence of alopecia areata in a patient receiving etanercept injections","volume":"141","author":"Posten","year":"2005","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0635","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1001\/archderm.142.12.1654","article-title":"Development of alopecia areata universalis in a patient receiving adalimumab","volume":"142","author":"Garcia Bartels","year":"2006","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0640","first-page":"892","article-title":"Development of alopecia areata after biological therapy with TNF\u2010alpha Blockers: description of a case and review of the literature","volume":"27","author":"Hernandez","year":"2009","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0645","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000113945","article-title":"Alopecia areata universalis elicited during treatment with adalimumab","volume":"216","author":"Pelivani","year":"2008","journal-title":"Dermatology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0650","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000162180","article-title":"Alopecia areata universalis during treatment of rheumatoid arthritis with anti\u2010TNF\u2010alpha anti\u2010 body (adalimumab)","volume":"217","author":"Chaves","year":"2008","journal-title":"Dermatology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0655","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000111523","article-title":"Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab","volume":"216","author":"Fabre","year":"2008","journal-title":"Dermatology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0660","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1468-3083.2010.03770.x","article-title":"Alopecia areata as another immune\u2010mediated disease developed in patients treated with tumour necrosis factor\u2010alpha blocker agents: Report of five cases and review of the literature","volume":"25","author":"Ferran","year":"2011","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0665","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/archderm.142.12.1653","article-title":"Alopecia areata during treatment with biologic agents","volume":"142","author":"Tosti","year":"2006","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0670","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF\u2010targeted therapies: analysis of233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0675","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/03009740902922612","article-title":"Immune\u2010mediated skin lesions in patients treated with anti\u2010tumour necrosis factor alpha inhibi\u2010 tors","volume":"38","author":"Exarchou","year":"2009","journal-title":"Scand J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0680","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12016-011-8262-2","article-title":"Skin Manifestations Induced by TNF\u2010Alpha Inhibitors in Juvenile Idiopathic Arthritis","volume":"42","author":"Pontikaki","year":"2012","journal-title":"Clin Rev Allergy Immunol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0685","first-page":"1955","article-title":"Leukocytoclastic vasculitis associated with tumor necrosis factor\u2010alpha blocking agents","volume":"31","author":"Mohan","year":"2004","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0690","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/s10165-009-0232-7","article-title":"Cutaneous vasculitis induced by TNF inhibitors: a report of three cases","volume":"20","author":"Fujikawa","year":"2010","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0695","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000081494","article-title":"Infliximab\u2010induced vitiligo","volume":"210","author":"Ramirez-Hernandez","year":"2005","journal-title":"Dermatology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0700","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3899\/jrheum.100968","article-title":"Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti\u2010tumor necrosis factor therapy","volume":"38","author":"Lahita","year":"2011","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0705","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/rheumatology\/ker144","article-title":"Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists","volume":"50","author":"Hernandez","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0710","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/art.22358","article-title":"Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor","volume":"55","author":"Hall","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0715","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-009-1370-1","article-title":"Etanercept\u2010induced anti\u2010Jo\u20101\u2010antibody\u2010positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature","volume":"29","author":"Ishikawa","year":"2010","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0720","article-title":"Morphea associated with the use of adalimumab: a case report and review of the literature","author":"Ramirez","year":"2011","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0725","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.rhu.0000191162.66288.27","article-title":"Infliximab\u2010induced scleredema in a patient with rheumatoid arthritis","volume":"11","author":"Ranganathan","year":"2005","journal-title":"J Clin Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0730","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1684\/ejd.2010.0946","article-title":"Morphea, an unusual side effect of anti\u2010TNF\u2010alpha treatment","volume":"20","author":"Mattozzi","year":"2010","journal-title":"Eur J Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0735","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/ard.2007.075663","article-title":"Granuloma annulare induced by anti\u2010tumour necrosis factor therapy","volume":"67","author":"Voulgari","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0740","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.annder.2009.12.003","article-title":"Cutaneous events during anti\u2010TNF alpha therapy: a prospective observational study of 41 cases","volume":"137","author":"Bonnet","year":"2010","journal-title":"Ann Dermatol Venereol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0745","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000318008","article-title":"Autoimmune bullous skin diseases occurring under anti\u2010tumor necrosis factor therapy: two case reports","volume":"221","author":"Boussemart","year":"2010","journal-title":"Dermatology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0750","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1365-2230.2011.04102.x","article-title":"Drug\u2010induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept","volume":"36","author":"Kluk","year":"2011","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0755","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000243805","article-title":"Bullous pemphigoid during long\u2010term TNF\u2010alpha blocker therapy","volume":"219","author":"Bordignon","year":"2009","journal-title":"Dermatology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0760","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0765","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine","year":"2007","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0770","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/s10165-007-0632-5","article-title":"Anti\u2010tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis","volume":"17","author":"Kubota","year":"2007","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0775","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/rheumatology\/kel366","article-title":"Influenza vaccination as model for testing immune modulation induced by anti\u2010TNF and methotrexate therapy in rheumatoid arthritis patients","volume":"46","author":"Kapetanovic","year":"2007","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0780","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/ard.2011.152983","article-title":"Reduced seroprotection after pandemic H1N1 influenza adjuvant\u2010free vaccination in patients with rheumatoid arthritis: implications for clinical practice","volume":"70","author":"Ribeiro","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0785","doi-asserted-by":"crossref","unstructured":"Garrido Lopez BC, Navarro Compain MV, Navarro Sarabia F. [Vaccines and chemo\u2010prophylaxis in rhemautoid arthritis: is a vaccine calendar necessary?]. Reumatol Clin. Nov;7:412\u20106.","DOI":"10.1016\/j.reumae.2011.01.004"},{"key":"10.1016\/j.rbr.2014.06.006_bib0790","first-page":"4","article-title":"2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis","volume":"53","author":"Brenol","year":"2013","journal-title":"Rev Bras Reumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0795","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/01.rhu.0000166626.68898.17","article-title":"Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis","volume":"11","author":"Kremer","year":"2005","journal-title":"J Clin Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0800","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3899\/jrheum.091066","article-title":"Abatacept for rheumatoid arthritis: a Cochrane systematic review","volume":"37","author":"Maxwell","year":"2010","journal-title":"J Rheumatol."},{"issue":"Suppl 1","key":"10.1016\/j.rbr.2014.06.006_bib0805","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1297-319X(12)70011-8","article-title":"Abatacept therapy and safety management","volume":"79","author":"Pham","year":"2012","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.rbr.2014.06.006_bib0810","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/jrheum.120906","article-title":"Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program","volume":"40","author":"Weinblatt","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rbr.2014.06.006_bib0815","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.23397","article-title":"Results of a two\u2010year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate","volume":"58","author":"Kremer","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0820","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease\u2010modifying antirheumatic drugs: A one\u2010year randomized, placebo\u2010controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0825","first-page":"w13581","article-title":"Use of abatacept in rheumatoid arthritis","volume":"142","author":"von Kempis","year":"2012","journal-title":"Swiss Med Wkly."},{"key":"10.1016\/j.rbr.2014.06.006_bib0830","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.22750","article-title":"Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice","volume":"56","author":"Bigbee","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0835","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate\u2010resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rbr.2014.06.006_bib0840","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/ard.2008.097527","article-title":"Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment","volume":"68","author":"Simon","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 46","key":"10.1016\/j.rbr.2014.06.006_bib0845","first-page":"546","article-title":"Safety of T\u2010cell co\u2010stimulation modulation with abatacept in patients with rheumatoid arthritis","volume":"25","author":"Sibilia","year":"2007","journal-title":"Clin Exp. Rheumatol."},{"issue":"Suppl","key":"10.1016\/j.rbr.2014.06.006_bib0850","first-page":"5786","article-title":"Autoimmune adverse events in the abatacept RA clinical development program: a safety analysis with > 10000 person \u2013 years of exposure [abstract 1673]","volume":"58","author":"Smitten","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0855","series-title":"Response to influenza vaccine in rheumatoid arthritis patients with an inadequate response to anti\u2010TNF therapy treated with abatacept in the ARRIVE trial. Poster FRI 943\/175","author":"Schiff","year":"2007"},{"issue":"Suppl3","key":"10.1016\/j.rbr.2014.06.006_bib0860","first-page":"458","article-title":"Abatacept in association with traditional DMARDS severely impairs humoral response to pandemic A H1N1 influenza vaccination in rheumatoid arthritis patients","volume":"70","author":"Ribeiro","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0865","article-title":"Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti\u2010TNF therapy treated with abatacept in the ARRIVE trial","author":"Schiff","year":"2007","journal-title":"Poster SAT0029, EULAR"},{"key":"10.1016\/j.rbr.2014.06.006_bib0870","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti\u2010tumor necrosis factor therapy: results of a multicenter, randomized, double\u2010blind, placebo\u2010controlled, phase iii trial evaluating primary efficacy and safety at twenty\u2010four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0875","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody\u2010positive patients with rheumatoid arthritis and in those for whom no more than one previous tnf antagonist has failed: pooled data from 10 european registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0880","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.120573","article-title":"multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5\u2010year data from the reflex study","author":"Keystone","year":"2012","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0885","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-010-1526-y","article-title":"The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"31","author":"Lee","year":"2011","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.rbr.2014.06.006_bib0890","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-eular.2085","article-title":"long\u2010term safety of rituximab in rheumatoid arthritis: 9.5\u2010year follow\u2010up of the global clinical trial programme with a focus on adverse events of interest in ra patients","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0895","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0900","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta\u2010analyses of randomised placebo\u2010controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 6","key":"10.1016\/j.rbr.2014.06.006_bib0905","doi-asserted-by":"crossref","first-page":"vi37","DOI":"10.1093\/rheumatology\/kes283","article-title":"Overview of safety of non\u2010biologic and biologic DMARDs","volume":"51","author":"Ruderman","year":"2012","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0910","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab\u2010based regimens: a serious complication in both HBsAg\u2010positive and HBsAg\u2010negative patients","volume":"89","author":"Pei","year":"2010","journal-title":"Ann Hematol."},{"issue":"27","key":"10.1016\/j.rbr.2014.06.006_bib0915","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1200\/JCO.2009.21.9352","article-title":"Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative\/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis","volume":"20","author":"Koo","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0920","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"chronic hepatitis b guideline working party of the asian\u2010pacific association for the study of the liver. Asian\u2010pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int."},{"key":"10.1016\/j.rbr.2014.06.006_bib0925","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology."},{"issue":"Suppl 5","key":"10.1016\/j.rbr.2014.06.006_bib0930","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.22882","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis b virus infection","volume":"49","author":"Weinbaum","year":"2009","journal-title":"Hepatology."},{"key":"10.1016\/j.rbr.2014.06.006_bib0935","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/BOR.0b013e328338f6df","article-title":"The A, B, Cs of viral hepatitis in the biologic era","volume":"22","author":"Ferri","year":"2010","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0940","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/acr.20167","article-title":"Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?","volume":"62","author":"Yazdany","year":"2010","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0945","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","article-title":"American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients eeceiving cytotoxic chemotherapy for treatment of malignant diseases","volume":"28","author":"Artz","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0950","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0955","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0960","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/art.22811","article-title":"Development of psoriasis after B cell depletion with rituximab","volume":"56","author":"Dass","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2014.06.006_bib0965","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Non\u2010infectious pulmonary toxicity of rituximab: a systematic review","volume":"51","author":"Hadjinicolaou","year":"2012","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib0970","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib0975","first-page":"430","article-title":"Serum sickness following treatment with rituximab","volume":"34","author":"Todd","year":"2007","journal-title":"JRheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib0980","doi-asserted-by":"crossref","unstructured":"van Assen S, Agmon\u2010Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. eular recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis Mar. 70:414\u201022.","DOI":"10.1136\/ard.2010.137216"},{"key":"10.1016\/j.rbr.2014.06.006_bib0985","doi-asserted-by":"crossref","unstructured":"Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 62;1:64\u201074.","DOI":"10.1002\/art.25034"},{"key":"10.1016\/j.rbr.2014.06.006_bib0990","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157339711794474620","article-title":"Choice of biological therapy for patients with rheumatoid arthritis: The Infection Perspective","volume":"7","author":"Keyser","year":"2011","journal-title":"Curr Rheumatol Rev."},{"key":"10.1016\/j.rbr.2014.06.006_bib0995","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/rheumatology\/ker223","article-title":"Risk of infections in rheumatoid arthritis patients treated with tocilizumab","volume":"51","author":"Lang","year":"2012","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib1000","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3899\/jrheum.100717","article-title":"Tocilizumab for rheumatoid arthritis: a Cochrane systematic review","volume":"38","author":"Singh","year":"2011","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/s10165-010-0279-5","article-title":"Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with RA: meta\u2010analysis of six initial trials and five long\u2010term extensions","volume":"20","author":"Nishimoto","year":"2010","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/CMAMD.S7371","article-title":"Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis","volume":"5","author":"Ogata","year":"2012","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord."},{"key":"10.1016\/j.rbr.2014.06.006_bib1015","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab randomized clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.rbr.2014.06.006_bib1020","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta\u2010analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib1025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3109\/s10165-011-0577-6","article-title":"Radiological features and therapeutic responses of pulmonary nontuberculosis mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a restrospective multicenter study in Japan","volume":"22","author":"Mori","year":"2012","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1030","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2008.090068","article-title":"Laboratory and febrile features after joint surgery in patients with RA treated with tocilizumab","volume":"68","author":"Hirao","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib1035","article-title":"Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real\u2010world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study","author":"Momohara","year":"2012","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1040","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: \u00ednterim analysis of 3881 patients","volume":"70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib1045","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/s10165-009-0159-z","article-title":"Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases","volume":"19","author":"Nagamine","year":"2009","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3899\/jrheum.080930","article-title":"Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis","volume":"36","author":"Nakamura","year":"2009","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1060","first-page":"199","volume":"19","author":"Sugiura","year":"2009","journal-title":"A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab. Mod Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib1070","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/keq368","article-title":"Registries in rheumatoid arthritis and autoimune diseases: data from the French registries","volume":"50","author":"Mariette","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib1075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ab.2009.04.021","article-title":"Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti\u2010tocilizumab antibodies with control by surrogate standards","volume":"390","author":"Stubenrauch","year":"2009","journal-title":"Anal Biochem."},{"key":"10.1016\/j.rbr.2014.06.006_bib1080","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/rheumatology\/ker336","article-title":"Necrotizing fasciitis in a rheumatoid arthritis patient treated with tocilizumab","volume":"51","author":"van de Sande","year":"2012","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib1085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annder.2012.11.006","volume":"140","author":"Samimi","year":"2013","journal-title":"Ann Dermatol Venereol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1090","first-page":"270315","article-title":"Anti\u2010interleukin\u20106 receptor antibody therapy\u2010induced retinopathy in a patient with rheumatoid arthritis","volume":"2012","author":"Tada","year":"2012","journal-title":"Case Rep Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1095","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2169\/internalmedicine.50.5497","article-title":"A case of organizing pneumonia induced by tocilizumab","volume":"50","author":"Ikegawa","year":"2011","journal-title":"Intern Med."},{"key":"10.1016\/j.rbr.2014.06.006_bib1100","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1007\/s00296-010-1525-z","article-title":"A fatal case of acute exacerbation of intersticial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab","volume":"32","author":"Kawashiri","year":"2012","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.rbr.2014.06.006_bib1105","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3899\/jrheum.111166","article-title":"Psoriasis onset with tocilizumab treatment for rheumatoid arthritis","volume":"39","author":"Wendling","year":"2012","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1110","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3899\/jrheum.110170","article-title":"Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect?","volume":"38","author":"Wendling","year":"2011","journal-title":"J Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1115","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1365-2133.2010.10005.x","article-title":"Onset of psoriasis following treatment with tocilizumab","volume":"163","author":"Laurent","year":"2010","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1120","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","article-title":"Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis","volume":"71","author":"Mori","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rbr.2014.06.006_bib1125","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/s10165-012-0595-z","article-title":"Safety and response to influenza vaccine in patients with systemic\u2010onset juvenile idiopathic arthritis receiving tocilizumab","volume":"22","author":"Shinoki","year":"2012","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1130","first-page":"199","article-title":"Consensus of the Brazilian Society of Rheumatology for diagnosis and early assessment of rheumatoid arthritis","volume":"51","author":"da Mota","year":"2011","journal-title":"Rev Bras Reumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/IJWH.S6029","article-title":"The use of anti\u2010TNF medications for rheumatologic disease in pregnancy","volume":"2","author":"Clowse","year":"2010","journal-title":"Int J Womens Health."},{"key":"10.1016\/j.rbr.2014.06.006_bib1140","unstructured":"US Food and Drug Administration. United States FDA pharmaceutical pregnancy categories. Fed Regist 1980; 44: 37434\u201067. Ref: US Food and Drug Administration. http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/Labeling\/ucm093307.htm. Accessed in October 20th 2012."},{"key":"10.1016\/j.rbr.2014.06.006_bib1145","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ajg.2008.71","article-title":"Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy","volume":"104","author":"Kane","year":"2009","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 3","key":"10.1016\/j.rbr.2014.06.006_bib1150","first-page":"iii28","article-title":"Update on safety during pregnancy of biological agents and some immunosuppressive anti\u2010rheumatic drugs","volume":"47","author":"\u00d8stensen","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.rbr.2014.06.006_bib1155","first-page":"219","article-title":"Biologic therapy and pregnancy. A systematic literature review","volume":"36","author":"Bogas","year":"2011","journal-title":"Acta Reumatol Port."},{"key":"10.1016\/j.rbr.2014.06.006_bib1160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2796.2010.02239.x","article-title":"Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study","volume":"268","author":"N\u00f8rgaard","year":"2010","journal-title":"J Intern Med."},{"key":"10.1016\/j.rbr.2014.06.006_bib1165","unstructured":"European Surveillance of Congenital Anomalies Home Page. http:\/\/www.eurocat\u2010network.eu. Accessed in October 20th 2012."},{"key":"10.1016\/j.rbr.2014.06.006_bib1170","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1148\/126.2.445","volume":"126","author":"Barnes","year":"1978","journal-title":"Radiology"},{"key":"10.1016\/j.rbr.2014.06.006_bib1175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(08)60074-4","article-title":"Epidemiology and causes of preterm birth","volume":"371","author":"Goldenberg","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.rbr.2014.06.006_bib1180","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.rbr.2014.06.006_bib1185","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2036.2011.04967.x","article-title":"Review article: a decision\u2010making algorithm for the management of pregnancy in the inflammatory bowel disease patient","volume":"35","author":"Habal","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"10.1016\/j.rbr.2014.06.006_bib1190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1590\/S0482-50042013000200003","article-title":"Diretriz de artrite reumatoide \u2013 Diagn\u00f3stico","volume":"53","author":"Mota","year":"2013","journal-title":"Rev Bras Reumatol."},{"issue":"2","key":"10.1016\/j.rbr.2014.06.006_bib1195","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1590\/S0482-50042013000200004","article-title":"Diretriz de artrite reumatoide \u2013 Tratamento medicamentoso","volume":"53","author":"Mota","year":"2013","journal-title":"Rev Bras Reumatol."},{"key":"10.1016\/j.rbr.2014.06.006_bib1200","first-page":"474","article-title":"2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis","volume":"52","author":"Pereira","year":"2012","journal-title":"Rev Bras Reumatol."}],"container-title":["Revista Brasileira de Reumatologia"],"original-title":[],"language":"pt","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0482500414001752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0482500414001752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T19:34:25Z","timestamp":1598384065000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0482500414001752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":239,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0482500414001752"],"URL":"https:\/\/doi.org\/10.1016\/j.rbr.2014.06.006","relation":{},"ISSN":["0482-5004"],"issn-type":[{"value":"0482-5004","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seguran\u00e7a do uso de terapias biol\u00f3gicas para o tratamento de artrite reumatoide e espondiloartrites","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Reumatologia","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.rbr.2014.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}